Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Authors:
- Philip J. MeasePMPhilip J. Mease
- Alexis OgdieAOAlexis Ogdie
- John TesserJTJohn Tesser
- Natalie J. ShiffNSNatalie J. Shiff
- Iris LinILIris Lin
- Soumya D. ChakravartySCSoumya D. Chakravarty
- Michael KellemanMKMichael Kelleman
- Robert R. McLeanRMRobert R. McLean
- Aaron BroadwellABAaron Broadwell
- Arthur KavanaughAKArthur Kavanaugh
- Joseph F. MerolaJMJoseph F. Merola
Open Access
- 19 August 2023
- journal article
- research article
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 10 (6) , 1479-1501
Abstract
Introduction The aim of this work is to evaluate treatment persistence and clinical outcomes after 6 months of on-label guselkumab use in patients with rheumatologist-diagnosed active psoriatic arthritis (PsA) enrolled in the CorEvitas PsA/Spondyloarthritis Registry. Methods Participants with PsA who initiated and persisted with on-label guselkumab use post-Food and Drug Administration (FDA) approval for active PsA (7/13/2020; subcutaneous 100 mg at weeks 0, 4, and every 8 weeks) at their 6-month follow-up visit (occurring through 3/31/2023) comprised the primary analysis population (On-Label Persisters). Hierarchical, multiplicity-controlled primary and secondary outcomes were mean (95% confidence interval) changes from baseline at 6 months in clinical Disease Activity Index for PsA (cDAPSA; primary), Physician Global Assessment (PGA) of arthritis and psoriasis (visual analog scale [VAS] 0–100), patient-reported pain (VAS 0–100), and percent body surface area with psoriasis (%BSA). Paired t tests determined changes that were statistically significantly different from 0 (α = 0.05). Results Among 114 patients who initiated on-label guselkumab and had eligible baseline and 6-month visits, 90 (78.9%) had persistent use. Among these On-Label Persisters at baseline, mean duration of PsA symptoms = 13.6 years; mean cDAPSA, PGA, and patient-reported pain = 22.0, 42.3, and 57.0, respectively; 94.4% had a history of psoriasis (mean BSA 7.6%); and 18.9% and 73.3%, respectively, previously received 1 or ≥ 2 biologic/targeted synthetic disease-modifying antirheumatic drugs. The mean change (improvement) in cDAPSA was − 5.4 (− 8.5, − 2.3; p < 0.001) at 6 months. Significant mean improvements in PGA (− 19.0 [− 24.2, − 13.8]), patient-reported pain (− 9.1 [− 14.4, − 3.8]), and %BSA (− 5.1 [− 7.6, − 2.7]) were also observed (all p < 0.001). Conclusions In this real-world PsA population, generally characterized by longstanding, treatment-resistant, active disease at baseline, persistent guselkumab use in nearly 80% of patients with on-label use was accompanied by significant improvements in joint and skin symptoms and patient-reported pain at 6 months. These registry data support results from randomized clinical trials demonstrating the efficacy of guselkumab in improving PsA signs and symptoms. Trial Registration clinicaltrials.gov: NCT02530268. Graphic abstractKeywords
Funding Information
- Janssen Research and Development
This publication has 40 references indexed in Scilit:
- Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled StudyArthritis Care & Research, 2015
- The 5-point Investigator’s Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trialsJournal of Dermatological Treatment, 2013
- Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT‐F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI)Arthritis Care & Research, 2011
- Minimally Important Difference for Patient-reported Outcomes in Psoriatic Arthritis: Health Assessment Questionnaire and Pain, Fatigue, and Global Visual Analog ScalesThe Journal of Rheumatology, 2010
- RAPID3 (Routine Assessment of Patient Index Data) on an MDHAQ (Multidimensional Health Assessment Questionnaire): Agreement with DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) activity categories, scored in five versus more than ninety secondsArthritis Care & Research, 2010
- Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatmentAnnals of the Rheumatic Diseases, 2010
- Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis IndexAnnals of the Rheumatic Diseases, 2009
- Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritisArthritis Care & Research, 2008
- The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trialsArthritis & Rheumatism, 1993
- Measurement of patient outcome in arthritisArthritis & Rheumatism, 1980